K. H. Grabstein, J. Eisenman, and K. Shanebeck, Cloning of a T cell growth factor that interacts with the ? chain of the interleukin-2 receptor, Science, vol.264, pp.965-973, 1994.

J. D. Burton, R. N. Bamford, and C. Peters, A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokineactivated killer cells, Proc Natl Acad Sci U S A, vol.91, pp.4935-4944, 1994.

J. G. Giri, D. M. Anderson, S. Kumaki, L. S. Park, K. H. Grabstein et al.,

, IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2, J Leukoc Biol, vol.57, pp.763-769, 1995.

D. M. Anderson, S. Kumaki, and M. Ahdieh, Functional characterization of the human interleukin-15 receptor ? chain and close linkage of IL15RA and IL2RA genes, J Biol Chem, vol.270, pp.29862-29871, 1995.

J. G. Giri, S. Kumaki, and M. Ahdieh, Identification and cloning of a novel IL-15 binding protein that is structurally related to the ? chain of the IL-2 receptor, Embo J, vol.14, pp.3654-63, 1995.

M. K. Kennedy, M. Glaccum, and S. N. Brown, Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice, J Exp Med, vol.191, pp.771-80, 2000.

J. P. Lodolce, P. R. Burkett, D. L. Boone, M. Chien, and A. Ma, T cell-independent interleukin 15R? signals are required for bystander proliferation, J Exp Med, vol.194, pp.1187-94, 2001.

, RLI, an IL-15-IL-15R? Fusion Protein, Tumor Therapy Mol Cancer Ther, vol.8, issue.9, 2009.

X. C. Li, G. Demirci, and S. Ferrari-lacraz, IL-15 and IL-2: a matter of life and death for T cells in vivo, Nat Med, vol.7, pp.114-122, 2001.

T. A. Waldmann, Effective cancer therapy through immunomodulation, Annu Rev Med, vol.57, pp.65-81, 2006.

K. E. Ugen, M. A. Kutzler, and B. Marrero, Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation, Cancer Gene Ther, vol.13, pp.969-74, 2006.

W. Lasek, G. Basak, and T. Switaj, Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice, Cancer Immunol Immunother, vol.53, pp.363-72, 2004.

G. W. Basak, L. Zapala, P. J. Wysocki, A. Mackiewicz, M. Jakobisiak et al., Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model, Oncol Rep, vol.19, pp.1173-1182, 2008.

T. Kishida, H. Asada, and Y. Itokawa, Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma, Mol Ther, vol.8, pp.552-560, 2003.

D. Carlo, E. Comes, A. Basso, and S. , The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement, J Immunol, vol.165, pp.3111-3119, 2000.

R. Evans, J. A. Fuller, G. Christianson, D. M. Krupke, and A. B. Troutt, IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations, Cell Immunol, vol.179, pp.66-73, 1997.

M. Habibi, M. Kmieciak, L. Graham, J. K. Morales, H. D. Bear et al., Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis, Breast Cancer Res Treat, vol.114, pp.423-454, 2009.

S. Cao, J. D. Black, A. B. Troutt, and Y. M. Rustum, Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model, Cancer Res, vol.58, pp.3270-3274, 1998.

S. Cao, A. B. Troutt, and Y. M. Rustum, Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer, Cancer Res, vol.58, pp.1695-1704, 1998.

C. A. Klebanoff, S. E. Finkelstein, and D. R. Surman, IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T cells, Proc Natl Acad Sci U S A, vol.101, pp.1969-74, 2004.

M. A. Cheever, Twelve immunotherapy drugs that could cure cancers, Immunol Rev, vol.222, pp.357-68, 2008.

H. Kobayashi, J. A. Carrasquillo, C. H. Paik, T. A. Waldmann, and Y. Tagaya, Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15, Cancer Res, vol.60, pp.3577-83, 2000.

L. Zamai, C. Ponti, and P. Mirandola, NK cells and cancer, J Immunol, vol.178, pp.4011-4017, 2007.

S. Dubois, J. Mariner, T. A. Waldmann, and Y. Tagaya, IL-15R? recycles and presents IL-15 in trans to neighboring cells, Immunity, vol.17, pp.537-584, 2002.

E. Mortier, T. Woo, R. Advincula, S. Gozalo, and A. Ma, IL-15R? chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation, J Exp Med, vol.205, pp.1213-1238, 2008.

M. P. Rubinstein, M. Kovar, and J. F. Purton, Converting IL-15 to a superagonist by binding to soluble IL-15R?, Proc Natl Acad Sci, vol.103, pp.9166-71, 2006.

T. A. Stoklasek, K. S. Schluns, and L. Lefrancois, Combined IL-15/IL-15R? immunotherapy maximizes IL-15 activity in vivo, J Immunol, vol.177, pp.6072-80, 2006.

S. Dubois, H. J. Patel, M. Zhang, T. A. Waldmann, and J. R. Muller, Preassociation of IL-15 with IL-15R ?-IgG1-Fc enhances its activity on proliferation of NK and CD8 + /CD44 high T cells and its antitumor action, J Immunol, vol.180, pp.2099-106, 2008.

M. Epardaud, K. G. Elpek, and M. P. Rubinstein, Interleukin-15/interleukin-15R? complexes promote destruction of established tumors by reviving tumor-resident CD8 + T cells, Cancer Res, vol.68, pp.2972-83, 2008.
URL : https://hal.archives-ouvertes.fr/hal-01602340

G. Bouchaud, L. Garrigue-antar, and V. Sole, The exon-3-encoded domain of IL-15R? contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15R?, J Mol Biol, vol.382, pp.1-12, 2008.

N. D. Huntington, N. Legrand, and N. L. Alves, IL-15 trans-presentation promotes human NK cell development and differentiation in vivo, J Exp Med, vol.206, pp.25-34, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-02442774

E. Mortier, A. Quemener, and P. Vusio, Soluble interleukin-15 receptor ? (IL-15R?)-sushi as a selective and potent agonist of IL-15 action through IL-15R?/?. Hyperagonist IL-15 × IL-15R? fusion proteins, J Biol Chem, vol.281, pp.1612-1621, 2006.

J. Bernard, C. Harb, and E. Mortier, Identification of an interleukin-15? receptor-binding site on human interleukin-15, J Biol Chem, vol.279, pp.24313-24335, 2004.

M. V. Cespedes, C. Espina, and M. A. Garcia-cabezas, Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites, Am J Pathol, vol.170, pp.1077-85, 2007.

P. Lehours, S. Raher, S. Dubois, J. Guo, A. Godard et al., Subunit structure of the high and low affinity human interleukin-15 receptors, Eur Cytokine Netw, vol.11, pp.207-222, 2000.

S. A. Rosenberg, J. C. Yang, and S. L. Topalian, Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using highdose bolus interleukin 2, JAMA, vol.271, pp.907-920, 1994.

R. Baluna and E. S. Vitetta, Vascular leak syndrome: a side effect of immunotherapy, Immunopharmacology, vol.37, pp.117-149, 1997.

P. C. Simmonds, Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group, BMJ, vol.321, pp.531-536, 2000.

R. N. Schwartz, L. Stover, and J. Dutcher, Managing toxicities of high-dose interleukin-2, Oncology (Williston Park), vol.16, pp.11-20, 2002.

T. A. Waldmann, S. Dubois, and Y. Tagaya, Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy, Immunity, vol.14, pp.105-115, 2001.

J. Rowley, A. Monie, C. F. Hung, and T. C. Wu, Inhibition of tumor growth by NK1.1 + cells and CD8 + T cells activated by IL-15 through receptor ?/common ? signaling in trans, J Immunol, vol.181, pp.8237-8284, 2008.

A. Jemal, R. Siegel, and E. Ward, Cancer statistics, CA Cancer J Clin, vol.58, pp.71-96, 2008.

B. M. Wolpin and R. J. Mayer, Systemic treatment of colorectal cancer, Gastroenterology, vol.134, pp.1296-310, 2008.

L. B. Saltz, J. V. Cox, and C. Blanke, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med, vol.343, pp.905-919, 2000.

R. M. Goldberg, D. J. Sargent, and R. F. Morton, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, vol.22, pp.23-30, 2004.